Insider Selling: Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Sells $283,800.00 in Stock

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.46, for a total value of $283,800.00. Following the sale, the chairman now owns 651,291 shares of the company’s stock, valued at approximately $6,161,212.86. This trade represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Poseida Therapeutics Stock Up 0.1 %

Shares of NASDAQ:PSTX opened at $9.51 on Friday. Poseida Therapeutics, Inc. has a 52-week low of $1.87 and a 52-week high of $9.58. The stock has a market cap of $929.83 million, a P/E ratio of -15.10 and a beta of 1.64. The business has a fifty day moving average of $4.57 and a two-hundred day moving average of $3.54. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68.

Institutional Investors Weigh In On Poseida Therapeutics

Hedge funds have recently modified their holdings of the company. Marshall Wace LLP purchased a new position in Poseida Therapeutics during the second quarter worth about $31,000. Rothschild Investment LLC purchased a new stake in shares of Poseida Therapeutics during the 2nd quarter valued at approximately $35,000. Principal Financial Group Inc. acquired a new position in Poseida Therapeutics in the second quarter valued at approximately $35,000. Virtu Financial LLC purchased a new position in Poseida Therapeutics in the third quarter worth approximately $37,000. Finally, Intech Investment Management LLC acquired a new stake in Poseida Therapeutics during the third quarter worth $46,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on PSTX shares. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Cantor Fitzgerald lowered shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 26th. HC Wainwright reissued a “neutral” rating and issued a $9.00 price target (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Piper Sandler cut shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research note on Monday, December 2nd. Finally, BTIG Research reissued a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.50.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.